Description

Product Name：Urolithin A Cocrystals

Active Ingredient：Urolithin A

Active Content：≥55%

Coformer：L-Carnitine

Technology ：Hydrogen-Bond Co-crystal Technology

Product Form：Crystalline Powder

Solubility：Up to 18× Higher

Blood Concentration：Up to 12× Higher

Muscle Concentration：Up to 20× Higher

Brain Tissue Concentration：Up to 4× Higher

Key Application：Advanced Nutritional & Dietary Supplement Formulations

Supply：Bulk Supply / OEM / Customized Development

 

1.Urolithin A Cocrystals — A New Solid-State Approach to Urolithin A

Urolithin A has become an important emerging ingredient in advanced nutritional and healthy-aging formulations.

However, conventional Urolithin A has a fundamental formulation challenge: very low water solubility, reported at around 10 ng/mL, together with oral bioavailability below 1%.

Poor solubility can limit dissolution and reduce the amount of active ingredient available for absorption.

For an ingredient intended for advanced nutritional applications, simply increasing the amount of conventional powder is not always an efficient formulation strategy.

Urolithin A Cocrystals take a different approach.

Instead of simply mixing Urolithin A with another ingredient, we use Co-crystal Technology to engineer the molecular arrangement of Urolithin A and L-Carnitine into a new crystalline structure.

The result is an advanced Urolithin A ingredient designed around one of the most important limitations of conventional UA: poor solubility and low bioavailability.

 

2.What Are Urolithin A Cocrystals?

A Co-crystal is a crystalline form composed of two or more solid components that interact at the molecular level through non-covalent interactions and form a defined, repeating crystal structure.

For this Urolithin A product, the technology uses Urolithin A and L-Carnitine to form a hydrogen-bonded Co-crystal.

The basic technical pathway is:

Urolithin A + L-Carnitine → Molecular Hydrogen Bonding → Supramolecular Self-Assembly → Co-crystal Formation → New Three-Dimensional Crystal Structure

The process is fundamentally different from physical blending.

In a simple physical mixture, Urolithin A and L-Carnitine remain two independent materials.

In a Co-crystal, molecular interactions between the components create an ordered supramolecular structure with a defined solid-state arrangement.

This changes the physicochemical properties of the active ingredient without changing the molecular structure of Urolithin A itself.

 

3.Hydrogen-Bond Co-crystal Technology

The core technology behind Urolithin A Cocrystals is Hydrogen-Bond Co-crystal Technology.

Hydrogen bonding and other non-covalent molecular interactions allow the active ingredient and coformer to undergo supramolecular self-assembly.

Through molecular stacking, assembly and ordered arrangement, the components form a stable three-dimensional crystalline network.

This Co-crystal structure can be engineered to improve important formulation properties such as:

• Solubility
• Dissolution
• Solid-state stability
• Physical properties
• Absorption performance
• Bioavailability

Therefore, the value of Urolithin A Cocrystals is not simply that another ingredient has been added to Urolithin A.

The key is that the active ingredient has been technically engineered into a different solid-state form.

 

4. 18× Higher Solubility

The poor water solubility of conventional Urolithin A is one of its most important formulation challenges.

According to the supplied product data, conventional Urolithin A has solubility of approximately 10 ng/mL.

Urolithin A Cocrystals are developed to overcome this limitation through Co-crystal engineering.

The product demonstrates up to 18× higher solubility, providing a significantly more favorable dissolution profile compared with conventional Urolithin A.

For formulation developers, improved solubility can provide greater flexibility when developing:

• Capsules
• Tablets
• Gummies
• Powder formulations
• Multi-active nutritional products

This makes Urolithin A Cocrystals particularly interesting for manufacturers looking for a more advanced form of Urolithin A rather than a conventional low-solubility raw material.

 

5.Enhanced Blood, Muscle and Brain Tissue Exposure

The value of improved solubility goes beyond the laboratory dissolution profile.

The supplied product data reports substantially increased Urolithin A concentrations following administration:

12× higher concentration in blood

20× higher concentration in muscle

4× higher concentration in brain tissue

These results highlight the potential of the Co-crystal approach to improve the overall exposure profile of Urolithin A.

For global ingredient buyers, this is an important differentiation point:

Urolithin A Cocrystals are not simply a higher-content Urolithin A powder. They represent a technology-driven approach designed to improve the performance of the active ingredient after formulation and administration.

 

6.From Conventional Urolithin A to Advanced Urolithin A Cocrystals

The formulation challenge of Urolithin A can be summarized as:

Low Solubility → Limited Dissolution → Low Oral Exposure → Formulation Challenge

The Co-crystal approach changes the technical pathway:

Urolithin A + L-Carnitine → Hydrogen-Bond Co-crystal → Improved Solid-State Properties → Higher Solubility → Improved Exposure

This is the key value of Urolithin A Cocrystals.

Rather than relying solely on higher dosage or conventional excipient-based formulation strategies, Co-crystal Technology addresses the physicochemical properties of the active ingredient itself.

 

Urolithin A Cocrystals vs Conventional Urolithin A

Property	Conventional Urolithin A	Urolithin A Cocrystals
Active Ingredient	Urolithin A	Urolithin A
Active Content	—	≥55%
Solid-State Form	Conventional UA	Co-crystal
Coformer	None	L-Carnitine
Technology	Conventional Material	Hydrogen-Bond Co-crystal Technology
Water Solubility	Around 10 ng/mL	Up to 18× higher
Oral Bioavailability	<1% reported for conventional UA	Enhanced exposure
Blood Concentration	Conventional	Up to 12× higher
Muscle Concentration	Conventional	Up to 20× higher
Brain Tissue Concentration	Conventional	Up to 4× higher
Formulation Positioning	Conventional UA ingredient	Advanced high-performance UA ingredient

 

8.A More Advanced Urolithin A Delivery Strategy

One important reason Urolithin A has attracted attention is its relationship with mitophagy, the cellular process responsible for removing damaged mitochondria.

However, conventional Urolithin A has an important practical limitation: natural dietary precursors such as ellagic acid depend on individual gut microbiota to be converted into Urolithin A.

The supplied technical material highlights that this conversion capability varies substantially between individuals and can decline with age.

This creates a clear distinction between:

Dietary precursor → Gut microbiota conversion → Urolithin A

and

Urolithin A Cocrystals → Direct Urolithin A supplementation

For ingredient developers, this makes direct Urolithin A supplementation particularly attractive when consistent active-ingredient intake is required.

The Co-crystal form then takes this approach one step further by addressing the solubility and bioavailability limitations of conventional Urolithin A.

 

9.Advanced Co-crystal Technology Platform

Co-crystal Technology is a formulation technology designed to improve the physicochemical properties of active ingredients without changing their molecular structure.

Through appropriate coformer selection and supramolecular molecular interactions, Co-crystals can be developed to improve:

01 — Stability
Improved resistance to oxidation and photodegradation.

02 — Physical Properties
Potentially improved melting behavior, hygroscopicity and mechanical properties.

03 — Solubility & Dissolution
Improved dissolution characteristics for poorly soluble active ingredients.

04 — Bioavailability
Improved absorption and systemic exposure.

For Urolithin A, the technology is specifically focused on overcoming the limitations of poor solubility and low oral bioavailability.

 

10.Advanced Ingredient Technology Platform

As a global supplier of nutritional ingredients and advanced ingredient technologies, we combine ingredient sourcing with technical evaluation and application-oriented development.

Our technology platform covers Co-crystal Technology, Co-amorphous Technology, Liposomal Technology, Microencapsulation Technology, Submicroencapsulation Technology, Microparticles, Pellet Technology and Granulation Technology, allowing different technical routes to be considered according to the characteristics of each active ingredient and target formulation.

For poorly soluble active ingredients such as Urolithin A, Co-crystal Technology provides a distinct solid-state engineering route that differs fundamentally from conventional powder processing or Microencapsulation.

 

11.Urolithin A Cocrystals for Advanced Nutritional Formulations

Urolithin A Cocrystals can be considered for a variety of modern nutritional dosage forms, including:

• Hard Capsules
• Softgels
• Tablets
• Gummies
• Powder Supplements
• Multi-Active Formulations

The improved solubility and exposure profile also creates greater formulation flexibility for products combining Urolithin A with other advanced nutritional ingredients.

For manufacturers developing premium healthy-aging, sports nutrition, mitochondrial-health or advanced nutritional formulations, Urolithin A Cocrystals offer a differentiated ingredient platform rather than a conventional UA raw material.

 

12.Formulation Synergy: Urolithin A Cocrystals + Co-crystal Ubiquinol

The supplied development concept also provides an interesting formulation direction combining Urolithin A Cocrystals with Co-crystal Ubiquinol.

The technical concept can be understood as complementary functions within mitochondrial nutrition:

Urolithin A Cocrystals
Focus on the Urolithin A pathway associated with mitochondrial quality control and mitophagy.

Co-crystal Ubiquinol
Provides an advanced form of reduced CoQ10 designed to improve solubility, stability and absorption.

This creates a formulation concept based on:

Mitochondrial Quality Control + Energy Support

For finished-product developers, the combination provides an opportunity to build a more differentiated multi-active formulation around two advanced Cocrystals rather than combining conventional raw materials.

This type of combination can be further evaluated according to target dosage form, market positioning and regulatory requirements.

 

13.Formulation Synergy: Urolithin A Cocrystals + S-Equol

Another formulation concept from the supplied technical material combines Urolithin A Cocrystals with S-Equol.

The concept is based on combining different nutritional mechanisms:

Urolithin A Cocrystals
Provides a direct Urolithin A ingredient in an advanced Co-crystal form.

S-Equol
Provides an additional ingredient route for women’s health formulations.

This combination may be considered for specialized women’s nutritional products where manufacturers want to integrate mitochondrial-focused ingredients with other targeted nutritional actives.

The specific formulation ratio, dosage and claims should always be evaluated according to the target market and applicable regulatory requirements.

 

14.B2B Supply of Urolithin A Cocrystals

We supply Urolithin A Cocrystals ≥55% for global ingredient buyers, dietary supplement manufacturers, nutritional product developers and formulation companies looking for advanced Urolithin A ingredients.

Compared with conventional Urolithin A, the Co-crystal form provides a much stronger technical proposition:

≥55% Active → 18× Higher Solubility → 12× Blood Concentration → 20× Muscle Concentration → 4× Brain Tissue Concentration

This makes Urolithin A Cocrystals particularly suitable for companies developing premium, science-driven and differentiated nutritional products.

We can support:

• Bulk ingredient supply
• Sample evaluation
• R&D formulation testing
• Application development
• OEM / ODM projects
• Customized Co-crystal development
• Multi-active formulation concepts

For new product development, we recommend starting with a sample so that your R&D team can evaluate dissolution, formulation compatibility, dosage-form performance and overall application suitability.

 

15.Customized Urolithin A Development & OEM

Different markets and finished products may require different active concentrations, dosage forms and processing characteristics.

We can discuss customized development according to:

• Urolithin A content
• Co-crystal formulation requirements
• Dosage form
• Powder characteristics
• Multi-active formulations
• Application requirements
• Bulk packaging
• OEM / customized ingredient projects

Our Co-crystal development approach focuses on matching the solid-state technology with the actual formulation challenge of the active ingredient.

 

16.Why Choose Urolithin A Cocrystals?

≥55% Urolithin A
High active content for advanced nutritional formulations.

Hydrogen-Bond Co-crystal Technology
Urolithin A and L-Carnitine form a defined molecular-level Co-crystal structure.

18× Higher Solubility
Addresses one of the key formulation limitations of conventional Urolithin A.

12× Higher Blood Concentration
Demonstrates substantially enhanced systemic exposure according to the supplied product data.

20× Higher Muscle Concentration
Highlights the improved tissue exposure profile reported for the Co-crystal form.

4× Higher Brain Tissue Concentration
Further demonstrates the differentiated exposure profile of Urolithin A Cocrystals.

≥55% Active Content + Advanced Solid-State Engineering
A differentiated alternative to conventional Urolithin A raw materials.

Flexible Formulation Potential
Suitable for capsules, tablets, gummies, softgels and powder formulations.

 

FAQ

1.What are Urolithin A Cocrystals?

Urolithin A Cocrystals are an advanced crystalline form of Urolithin A produced using 2.Hydrogen-Bond Co-crystal Technology. Urolithin A is combined with L-Carnitine at the molecular level through non-covalent interactions to form a defined Co-crystal structure.

3.What is the active content?

The active Urolithin A content is ≥55%.

4.What coformer is used?

The supplied product uses L-Carnitine as the coformer.

5.How are Urolithin A Cocrystals different from a physical mixture?

A physical mixture simply blends Urolithin A and L-Carnitine. In a Co-crystal, the components interact at the molecular level through hydrogen bonding and form an ordered crystalline structure.

6.What is the main advantage of Urolithin A Cocrystals?

The key advantage is improved physicochemical performance. Product data reports 18× higher solubility, 12× higher blood concentration, 20× higher muscle concentration and 4× higher brain tissue concentration.

7.Are Urolithin A Cocrystals microencapsulated?

No. Urolithin A Cocrystals are based on Co-crystal Technology, a solid-state formulation technology. They should not be described as Microencapsulated Powder.

8.What dosage forms can use Urolithin A Cocrystals?

They can be considered for hard capsules, softgels, tablets, gummies and powder formulations, depending on the final formulation.

9.Can Urolithin A Cocrystals be combined with other advanced ingredients?

Yes. The supplied formulation concepts include combinations with Co-crystal Ubiquinol and S-Equol. Final formulation ratios and positioning should be evaluated according to the target product and applicable market requirements.

10.Do you provide samples and bulk supply?

Yes. We support sample evaluation, bulk ingredient supply and customized development for international B2B customers.